WO2000041508A3 - Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines - Google Patents
Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines Download PDFInfo
- Publication number
- WO2000041508A3 WO2000041508A3 PCT/US2000/001002 US0001002W WO0041508A3 WO 2000041508 A3 WO2000041508 A3 WO 2000041508A3 US 0001002 W US0001002 W US 0001002W WO 0041508 A3 WO0041508 A3 WO 0041508A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune cells
- cancer
- stimulatory molecules
- cytokines
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to methods and compositions for the treatment, prevention or inhibition of diseases and disorders, including cancer, inflammatory diseases or disorders, and infectious diseases, comprising compounds which augment activated immune cells, i.e., T-cells and natural killer ('NK') cells. In particular, the present invention relates to methods and compositions for the treatment, prevention or inhibition of diseases and disorders, including cancer, inflammatory diseases or disorders, and infectious diseases, comprising the administration of a compound that activates one or more cytokine receptors and a compound that activates one or more co-stimulatory molecules expressed by activated immune cells, i.e., activated T-cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32093/00A AU3209300A (en) | 1999-01-15 | 2000-01-14 | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11599299P | 1999-01-15 | 1999-01-15 | |
US60/115,992 | 1999-01-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000041508A2 WO2000041508A2 (en) | 2000-07-20 |
WO2000041508A3 true WO2000041508A3 (en) | 2000-11-02 |
Family
ID=22364611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001002 WO2000041508A2 (en) | 1999-01-15 | 2000-01-14 | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3209300A (en) |
WO (1) | WO2000041508A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US7651686B2 (en) | 2001-10-09 | 2010-01-26 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
DE10248141B4 (en) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nucleic acids and their use for gene therapy |
US8663622B2 (en) | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
AU2005295038B2 (en) | 2004-10-06 | 2012-05-17 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
ES2714708T3 (en) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedures for the treatment of cancer in patients with elevated levels of Bim |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US20210198374A1 (en) | 2018-04-17 | 2021-07-01 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
-
2000
- 2000-01-14 AU AU32093/00A patent/AU3209300A/en not_active Abandoned
- 2000-01-14 WO PCT/US2000/001002 patent/WO2000041508A2/en active Application Filing
Non-Patent Citations (10)
Title |
---|
CARROLL, MILES W. ET AL: "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), (DEC. 16, 1998) VOL. 90, NO. 24, PP. 1881-1887., XP000909585 * |
CHEMICAL ABSTRACTS, vol. 132, Columbus, Ohio, US; abstract no. 288382, MARTINET, OLIVIER ET AL: "Long-term remission of preestablished hepatic metastases from colorectal cancer by in vivo adenoviral-mediated transfer of interleukin-12 and 4-1BB ligand genes" XP002139305 * |
CHONG, H. ET AL: "Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity.", GENE THERAPY, (FEB., 1998) VOL. 5, NO. 2, PP. 223-232., XP000909569 * |
CHU N R ET AL: "Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.", JOURNAL OF IMMUNOLOGY, (1997 APR 1) 158 (7) 3081-9., XP000887236 * |
COUDERC, BETTINA ET AL: "Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.", CANCER GENE THERAPY, (MAY-JUNE, 1998) VOL. 5, NO. 3, PP. 163-175., XP000886763 * |
GUO, Z. S. (1) ET AL: "Interleukin 12 and B7.1 costimulatory molecules coexpressed from an adenoviral vector act synergistically to induce antitumor response and suppress tumor formation in Lewis lung carcinoma model.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 255. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN, XP000887341 * |
KIM, YOUNG-JUNE ET AL: "Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses.", EUROPEAN JOURNAL OF IMMUNOLOGY, (MARCH, 1998) VOL. 28, NO. 3, PP. 881-890., XP000909420 * |
MELERO I ET AL: "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors", NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 3, no. 6, June 1997 (1997-06-01), pages 682 - 685-685, XP002104261, ISSN: 1078-8956 * |
PUTZER, BRIGITTE M. ET AL: "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997) VOL. 94, NO. 20, PP. 10889-10894., XP000887254 * |
SURG. FORUM (1999), 50, 297-299 * |
Also Published As
Publication number | Publication date |
---|---|
AU3209300A (en) | 2000-08-01 |
WO2000041508A2 (en) | 2000-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2561874A3 (en) | Pharmaceutical compositions for treating cancer | |
WO2005009355A3 (en) | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy | |
CA2505128A1 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
IL146950A0 (en) | Recombinant anti-cd40 antibody and uses thereof | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
WO2005018555A3 (en) | Lipid-modified immune response modifiers | |
AU2003301190A1 (en) | Administration of capsaicinoids | |
GEP20063741B (en) | Nonaryl-Heterocyclic NMDA/NR2B Antagonists | |
TNSN04113A1 (en) | 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
WO2002070438A3 (en) | Compositions for delivering bisphosphonates | |
WO2004103274A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
WO2005079195A3 (en) | Pyrazolopyridines and analogs thereof | |
EP1352897A3 (en) | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | |
GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
WO2000041508A3 (en) | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines | |
YU60900A (en) | Novel crystalline forms of an antiviral benzimidazole compound | |
EP1032556A4 (en) | Pharmaceutically active compounds and methods of use | |
AU3632600A (en) | Compositions and methods for the treatment of immune related diseases | |
BR9810755A (en) | CD 154 blocking therapy for therapeutic protein inhibitory syndrome | |
AU6921300A (en) | Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof | |
AU3434601A (en) | Compositions and methods for the treatment of immune related diseases | |
AU2002315485A1 (en) | Compositions and methods for the treatment of body weight disorders, including obesity | |
WO2002076930A3 (en) | Substituted diarylureas as stimulators for fas-mediated apoptosis | |
ITRM950589A0 (en) | USE OF NATURAL CYTOKINE MUTEINS AS IMMUNOGENS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT OR PREVENT DISEASES CAUSED BY THE OVERPRODUCTION OF THESE NATURAL CYTOKINES, AND PHARMACEUTICAL COMPOSITIONS SO OBTAINABLE | |
AU2001255168A1 (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |